Literature DB >> 22797877

Very high efficacy of intermediate-dose cytarabine in combination with G-CSF as a second-line mobilization of hematopoietic stem cells.

Tomasz Kruzel, Maria Sadus-Wojciechowska, Jacek Najda, Tomasz Czerw, Magdalena Glowala-Kosinska, Jerzy Holowiecki, Sebastian Giebel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22797877     DOI： 10.1007/s12185-012-1135-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  9 in total

Review 1.  Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy.

Authors:  S Siena; R Schiavo; P Pedrazzoli; C Carlo-Stella
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

2.  The EBMT activity survey 2009: trends over the past 5 years.

Authors:  H Baldomero; M Gratwohl; A Gratwohl; A Tichelli; D Niederwieser; A Madrigal; K Frauendorfer
Journal:  Bone Marrow Transplant       Date:  2011-02-28       Impact factor: 5.483

3.  Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells.

Authors:  Grzegorz W Basak; Ozren Jaksic; Zdenek Koristek; Gabor Mikala; Sandra Basic-Kinda; Jiri Mayer; Tamas Masszi; Sebastian Giebel; Boris Labar; Wieslaw Wiktor-Jedrzejczak
Journal:  Eur J Haematol       Date:  2011-04-01       Impact factor: 2.997

4.  Bone Marrow Transplantation: Prognostic Factors of Peripheral Blood Stem Cell Mobilization with Cyclophosphamide and Filgrastim (r-metHuG-CSF): The CD34+ Cell Dose Positively Affects the Time to Hematopoietic Recovery and Supportive Requirements after High-Dose Chemotherapy.

Authors:  C. Solá; P. Maroto; R. Salazar; R. Mesía; L. Mendoza; J. Brunet; A. López-Pousa; J. M. Tabernero; J. Montesinos; C. Pericay; C. Martínez; J. A. Cancelas; J. J. López-López
Journal:  Hematology       Date:  1999       Impact factor: 2.269

5.  European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.

Authors:  K Hübel; M M Fresen; J F Apperley; G W Basak; K W Douglas; I H Gabriel; C Geraldes; O Jaksic; Z Koristek; N Kröger; F Lanza; R M Lemoli; G Mikala; D Selleslag; N Worel; M Mohty; R F Duarte
Journal:  Bone Marrow Transplant       Date:  2011-11-14       Impact factor: 5.483

Review 6.  Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens.

Authors:  E Jantunen; S Fruehauf
Journal:  Bone Marrow Transplant       Date:  2011-01-10       Impact factor: 5.483

Review 7.  Improving stem cell mobilization strategies: future directions.

Authors:  W Bensinger; J F DiPersio; J M McCarty
Journal:  Bone Marrow Transplant       Date:  2009-01-12       Impact factor: 5.483

8.  Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

Authors:  Iskra Pusic; Shi Yuan Jiang; Scott Landua; Geoffrey L Uy; Michael P Rettig; Amanda F Cashen; Peter Westervelt; Ravi Vij; Camille N Abboud; Keith E Stockerl-Goldstein; Diane S Sempek; Angela L Smith; John F DiPersio
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742

9.  Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H.

Authors:  M Montillo; A Tedeschi; V Rossi; R Cairoli; E Pungolino; L Intropido; A M Cafro; G D'Avanzo; R Farioli; B Brando; B Scarpati; S Veronese; E Morra
Journal:  Leukemia       Date:  2004-01       Impact factor: 11.528
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.